JP2005503391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503391A5 JP2005503391A5 JP2003522527A JP2003522527A JP2005503391A5 JP 2005503391 A5 JP2005503391 A5 JP 2005503391A5 JP 2003522527 A JP2003522527 A JP 2003522527A JP 2003522527 A JP2003522527 A JP 2003522527A JP 2005503391 A5 JP2005503391 A5 JP 2005503391A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- administered
- quetiapine
- zolmitriptan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 44
- 238000009472 formulation Methods 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 33
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 23
- 229960001360 zolmitriptan Drugs 0.000 claims 23
- 229960004431 quetiapine Drugs 0.000 claims 22
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 22
- 208000019695 Migraine disease Diseases 0.000 claims 8
- 206010027599 migraine Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008024 pharmaceutical diluent Substances 0.000 claims 3
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical group [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960005197 quetiapine fumarate Drugs 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102855A SE0102855D0 (sv) | 2001-08-27 | 2001-08-27 | Method of treatment |
| PCT/SE2002/001507 WO2003018009A1 (en) | 2001-08-27 | 2002-08-23 | A combination of quetiapine and zolmitriptan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503391A JP2005503391A (ja) | 2005-02-03 |
| JP2005503391A5 true JP2005503391A5 (enExample) | 2006-01-05 |
Family
ID=20285147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003522527A Pending JP2005503391A (ja) | 2001-08-27 | 2002-08-23 | クエチアピンおよびゾルミトリプタンの配合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20050020571A1 (enExample) |
| EP (1) | EP1423112B1 (enExample) |
| JP (1) | JP2005503391A (enExample) |
| AT (1) | ATE342720T1 (enExample) |
| AU (1) | AU2002326271B2 (enExample) |
| CA (1) | CA2456480A1 (enExample) |
| DE (1) | DE60215525T2 (enExample) |
| ES (1) | ES2274081T3 (enExample) |
| NZ (1) | NZ530930A (enExample) |
| SE (1) | SE0102855D0 (enExample) |
| WO (1) | WO2003018009A1 (enExample) |
| ZA (1) | ZA200401550B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2522344A1 (en) * | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
| US7495024B2 (en) | 2006-08-07 | 2009-02-24 | Via Pharmaceuticals, Inc. | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque |
| US20110212980A1 (en) * | 2008-10-22 | 2011-09-01 | Novartis Ag | Combinations for the treatment of migraine |
| US20110091435A1 (en) * | 2008-10-24 | 2011-04-21 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of hair loss |
| US10457299B2 (en) * | 2017-02-22 | 2019-10-29 | Westinghouse Air Brake Technologies Corporation | Train stop timer |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| EP0906104A4 (en) * | 1996-03-25 | 2003-12-10 | Lilly Co Eli | PAIN TREATMENT PROCESS |
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| GB9709815D0 (en) * | 1997-05-14 | 1997-07-09 | Merck Sharp & Dohme | Therapeutic method |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
-
2001
- 2001-08-27 SE SE0102855A patent/SE0102855D0/xx unknown
-
2002
- 2002-08-23 AU AU2002326271A patent/AU2002326271B2/en not_active Ceased
- 2002-08-23 ES ES02760969T patent/ES2274081T3/es not_active Expired - Lifetime
- 2002-08-23 US US10/487,701 patent/US20050020571A1/en not_active Abandoned
- 2002-08-23 DE DE60215525T patent/DE60215525T2/de not_active Expired - Lifetime
- 2002-08-23 EP EP02760969A patent/EP1423112B1/en not_active Expired - Lifetime
- 2002-08-23 JP JP2003522527A patent/JP2005503391A/ja active Pending
- 2002-08-23 CA CA002456480A patent/CA2456480A1/en not_active Abandoned
- 2002-08-23 NZ NZ530930A patent/NZ530930A/en not_active IP Right Cessation
- 2002-08-23 AT AT02760969T patent/ATE342720T1/de not_active IP Right Cessation
- 2002-08-23 WO PCT/SE2002/001507 patent/WO2003018009A1/en not_active Ceased
-
2004
- 2004-02-25 ZA ZA200401550A patent/ZA200401550B/en unknown
-
2007
- 2007-11-07 US US11/936,244 patent/US20080108596A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2222522T3 (es) | Tratamiento de la migraña utilizando metoclopramida y un nsaid. | |
| RU2153337C2 (ru) | Таблетка парацетамола и домперидона с пленочным покрытием | |
| JP2010525050A5 (enExample) | ||
| JP2005515966A5 (enExample) | ||
| JP2005537268A5 (enExample) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2011098964A5 (enExample) | ||
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| JP2015512406A5 (enExample) | ||
| JP2008534552A (ja) | 血栓症治療用の新規な医薬組成物 | |
| JP2011529968A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2009517411A5 (enExample) | ||
| EP3150201A1 (en) | Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation | |
| KR20250069704A (ko) | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 | |
| JPWO2021099783A5 (enExample) | ||
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| EP1083932A1 (en) | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine | |
| JP2004525940A5 (enExample) | ||
| JP2005503391A5 (enExample) | ||
| CN102137664B (zh) | 具有被边界隔开的有效成分的固体药物制剂 | |
| JP2015515974A5 (enExample) | ||
| EP1567133B1 (en) | Pharmaceutical antiviral compositions | |
| EA012261B1 (ru) | Лекарственные формы, содержащие ингибитор протонного насоса и прокинетический агент | |
| JP2008533022A5 (enExample) |